HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Belmay/TFF merger

This article was originally published in The Rose Sheet

Executive Summary

New York City-based fragrance supplier Belmay and Amityville, N.Y.-based fragrance developer Technology Flavors & Fragrances will have combined sales of more than $60 mil. following planned merger announced Nov. 20. Agreement would call for Belmay to purchase 75% of TFF, which would change its name to Belmay/TFF and reconstitute its board of directors, firm says. Belmay President/CEO Ted Kesten will be appointed chairman/CEO of combined entity, while TFF Chairman/CEO Philip Rosner will become vice chair. Merger will help transform TFF into "world-class global developer and manufacturer of flavors and fragrances" by providing access to Belmay's solid infrastructure and international operations, TFF says. Move follows restructuring announcement by TFF prompted by consecutive sales losses ("The Rose Sheet" Nov. 19, In Brief)...

You may also be interested in...



TFF/Belmay terminate proposed merger

Fragrance developer Technology Flavors & Fragrances and fragrance supplier Belmay have terminated proposed merger discussions in a mutual agreement, the two companies announce Jan. 16. "Although the TFF/Belmay combination would have created a much larger entity in terms of sales volume...the proposed merger was not in the interest of our shareholders," Amityville, N.Y.-based TFF states. The two firms entered into the proposed agreement in November; merger was projected to result in combined sales of $60 mil. for the two firms (11"The Rose Sheet" Nov. 26, 2001, In Brief)...

UCB Pins Growth Hopes On Burgeoning Late-Stage Pipeline

UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.

 

New Indications For Diabetes Drugs Under The Spotlight At EMA

Janssen and AstraZeneca are among a raft of companies that might this week find out whether the European Medicines Agency will recommend approval of their products for expanded therapeutic indications.

UsernamePublicRestriction

Register

RS009822

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel